US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
uniQure N.V. - Ordinary Shares
(NQ:
QURE
)
23.46
+0.09 (+0.39%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about uniQure N.V. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
uniQure N.V. (QURE) Class Action Lawsuit Seeks Recovery for Investors; April 13, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
March 05, 2026
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds uniQure N.V. Investors of Upcoming Deadline
March 05, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE
March 04, 2026
From
SkyMedia, LLC
Via
GlobeNewswire
uniQure (NASDAQ:QURE) Stock Plummets 40% Despite Earnings Beat on FDA Setback for AMT-130
↗
March 02, 2026
Via
Chartmill
Topics
Earnings
uniQure N.V. (QURE) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
March 04, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
uniQure N.V. (QURE) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - Contact Kessler Topaz Meltzer & Check, LLP
March 04, 2026
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
March 03, 2026
From
Kahn Swick & Foti, LLC
Via
GlobeNewswire
Kaplan Fox Alerts Investors of uniQure N.V. (QURE) to a Securities Class Action Deadline on April 13, 2026
March 03, 2026
NEW YORK, NY - March 3, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) on behalf...
Via
TheNewswire.com
Topics
Lawsuit
Kaplan Fox Alerts Investors of uniQure N.V. (QURE) to a Securities Class Action Deadline on April 13, 2026
March 03, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QURE
March 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP; April 13, 2026, Lead Plaintiff Deadline
March 03, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP; April 13, 2026, Lead Plaintiff Deadline
March 03, 2026
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm
March 03, 2026
From
Schall Law
Via
GlobeNewswire
These Analysts Cut Their Forecasts On uniQure Following Q4 Results
↗
March 03, 2026
uniQure (NASDAQ:QURE) reported positive Q4 results, but FDA advised against using data for market application of AMT-130. Stock down 13.3%.
Via
Benzinga
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V.
March 03, 2026
From
Bernstein Liebhard LLP
Via
GlobeNewswire
Iran, Dip-Buyers & a Rare Buffett Stumble: Wall Street Shakes Off Its Worst Fears
↗
March 03, 2026
Via
Chartmill
Monday's session: top gainers and losers
↗
March 02, 2026
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
March 02, 2026
Via
Chartmill
uniQure (QURE) Q4 2025 Earnings Call Transcript
↗
March 02, 2026
uniQure (QURE) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Get insights into the top gainers and losers of Monday's pre-market session.
↗
March 02, 2026
Via
Chartmill
Why Did QURE Stock Almost Halve Pre-Market Today?
↗
March 02, 2026
uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.
Via
Stocktwits
uniQure Announces 2025 Financial Results and Provides Recent Company Updates
March 02, 2026
From
uniQure Inc.
Via
GlobeNewswire
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
March 02, 2026
From
uniQure Inc.
Via
GlobeNewswire
Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline
February 28, 2026
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline
February 28, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
uniQure N.V. (QURE) Investors: April 13, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP
February 27, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Fraud
Lawsuit
uniQure N.V. (QURE) Investors: April 13, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP
February 27, 2026
Did you buy QURE ordinary shares between September 24, 2025, and October 31, 2025?
Via
TheNewswire.com
Topics
Fraud
Lawsuit
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks?
↗
February 27, 2026
Analysts are divided on the target, with RBC Capital and Stifel saying the comments appeared to reference uniQure, while Leerink argued they more closely align with Regenxbio’s RGX-121.
Via
Stocktwits
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
February 26, 2026
Via
Chartmill
FDA Commissioner Refers To Rare Disease Drug With Associated Morbidity: Analysts Are Divided If Makary Meant Regenxbio Or Uniqure’s Experimental Therapy
↗
February 26, 2026
Following the comments, shares of both Regenxbio and uniQure traded in the red.
Via
Stocktwits
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
